Kidney failure and analgesic drugs

Gerald Faich, Edward B. Nelson, Rivka S. Horowitz, Vickie L. Wilson, Richard C. Dart, Thomas V. Perneger, Paul K. Whelton, Michael J. Klag

Research output: Contribution to journalLetter

Abstract

To the Editor: The case—control study by Perneger et al. (Dec. 22 issue)1 on the association of end-stage renal disease (ESRD) with analgesic drugs reaches inappropriate conclusions that are based on flawed methods. Fundamental to the validity of case—control studies is the requirement that the control population be similar to the case-patient population except for the case-defining characteristic.2 The authors compared predominantly black (54 percent) and male (58 percent) case patients with mainly nonblack (86 percent) and female (65 percent) control subjects. The adjustments made do not deal with the probable differences in the socioeconomic, educational, and residential (urban vs).

Original languageEnglish (US)
Pages (from-to)1514-1516
Number of pages3
JournalNew England Journal of Medicine
Volume332
Issue number22
DOIs
StatePublished - Jun 1 1995

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Kidney failure and analgesic drugs'. Together they form a unique fingerprint.

  • Cite this

    Faich, G., Nelson, E. B., Horowitz, R. S., Wilson, V. L., Dart, R. C., Perneger, T. V., Whelton, P. K., & Klag, M. J. (1995). Kidney failure and analgesic drugs. New England Journal of Medicine, 332(22), 1514-1516. https://doi.org/10.1056/NEJM199506013322213